-
The three companies have jointly conducted clinical trials of antibody-coupled drugs to treat urethra skin cancer
Time of Update: 2021-02-22
recently, Seattle Genetics and Astellas announced a partnership agreement with Mercedon to jointly conduct clinical trials of the antibody conceding drug (ADC) Enfortumab Vedotin and Keytruda for the first-line treatment of locally advanced or metastatic urethra cancer.
-
Bayer's two-year data confirm eeylea's effectiveness
Time of Update: 2021-02-22
Dr Jackie Napier, medical director of Bayer Ophthalmology, said: "Treatment of wet AMD has a profound impact on the ability of the NHS to be over-stressed and on the lives of people with the disease and their carers." The data are important because they once again confirm the evidence available for proactive T-E therapies and offer clinicians the possibility of reducing the number of injections needed to save vision," she continued.
-
New hepatitis C drug! Gileadji III Epclusa has been approved by Japan for the treatment of hepatitis C type 1-6
Time of Update: 2021-02-17
, a hepatitis C treatment giant, recently announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Epclusa (sofosbuvir 400mg/velpatasvir 100mg) for treatment: (1) adults infected with chronic hepatitis C virus (HCV) accompanied by uncompensated cirrhosis of the liver, and (2) people infected with chronic HCV without cirrhosis or compensation for cirrhosis of the liver who have received direct antiviral therapy (DAA).
-
New antipsychotic drugs! Lingbei and Otsuka Brexpiprazole Treat Post-Traumatic Stress Disorder (PTSD) Phase II Clinical Master:
Time of Update: 2021-02-17
The study, a randomized, double-blind, placebo and active drug control Phase II study, was launched in 2017 and included 321 adult PTSD patients to assess the efficacy, safety and tolerability of flexible dose brexpiprazole as a single-drug therapy and in combination therapy with flexible dose sertraline.
-
New hepatitis B drug in China! Vemlidy, the safest new drug in Gilead's history, is available in China
Time of Update: 2021-02-17
with the launch of Vemlidy, clinicians in China can now offer hepatitis B patients a new drug that retains TDF efficacy while improving kidney and bone safety parameters.
-
Cancer is the first innovative drug! Ono Pharmaceuticals filed a listing application for NON-7643 in Japan
Time of Update: 2021-02-17
Ono Pharmaceuticals of Japan recently announced that it has filed a listing application for ONO-7643, a gastric hunger agent (ghrelin) permutation agent used to improve weight loss and anorexia in patients with cancer.
-
New anti-inflammatory drugs! The FDA grants oral JAK/SYK dual-acting inhibitor ASN002 to treat the rapid pass of adiotic dermatitis:
Time of Update: 2021-02-17
Asana CEO and Founder Sandeep Gupta said, "We are pleased that the FDA has granted ASN002 fast track qualification, which reflects the importance of accelerating the development of new drugs to treat challenging skin/inflammatory diseases that have a significant impact on patient life." We look forward to interacting well with the FDA throughout the development of ASN002 and accelerating the clinical development of ASN002.
-
Roche breast cancer drug Patoju monoantigen has been approved for sale
Time of Update: 2021-02-17
Recently, the State Drug Administration approved the import registration application for Pertuzumab Injection, a combination of cocoonumab monoantigen and chemotherapy for complementary treatment of human skin growth factor 2 (HER2) positive early breast cancer patients with a high risk of recurrence.
-
Sword refers to Roche Hessetin! Celltrion/Teva biosimilar Herzuma (Curto bead monoanti) has been approved by the FDA:
Time of Update: 2021-02-17
South Korean biopharmaceutical company Celltrion and partner Teva recently announced that the U.S. Food and Drug Administration (FDA) has approved the trastuzumab-pkrb, an anti-biosimilar, for HER2-positive breast cancer treatment.
-
Lynparza received FDA approval to treat ovarian cancer
Time of Update: 2021-02-17
AstraZeneca and MSD announced that Lynparza has been approved by the FDA for first-line maintenance treatment for advanced ovarian cancer with BRCA mutations, further expanding the use of the drug.
-
The new drug for sickle cell disease has been approved by the FDA as a breakthrough drug
Time of Update: 2021-02-17
. Novartis, the Swiss pharmaceutical giant, recently announced that the U.S. Food and Drug Administration (FDA) has granted Crizanlizumab (SEG101, formerly Known as SelG1) a breakthrough drug qualification (BTD) to prevent vascular obstructive vision (VOC) in all patients with genotype sickle cell disease (SCD).
-
New antibiotics can treat blindness in the eyes of mice
Time of Update: 2021-02-17
team of researchers from britain, the United States, Japan and Germany has developed an antibiotic that kills a bacterium necessary for larvae to grow in parasites that cause river blindness.
-
New drug for ovarian cancer! Clovis company PARP inhibitor Rubraca single drug maintenance treatment for relapsed ovarian cancer by the European Union CHM: .
Time of Update: 2021-02-17
Clovis Oncology recently announced that the European Medicines Agency (EMA) Committee on Human Pharmaceutical Products (CHMP) has issued a positive opinion recommending the approval of rucaparib, an additional adaptive drug targeted at cancer, as a single-drug therapy for adults with relapsed (full or partially relieved) relapsed epithelial ovarian, fallopian and primary peritonal cancer.
-
Ocean-sourced anti-cancer drug Alidin approved: the first new type of multiple myeloma therapy
Time of Update: 2021-02-17
Recently, the company announced that the Australian Medicines Agency (TGA) has approved the drug Alidin (plitidepsin) for the treatment of patients with recurring or resuscable multiple myeloma (MM) who have failed or are resistant to other therapies.
-
New chinese epilepsy drug! Ukip Vimpat is approved for use in adolescent and adult epilepsy patients
Time of Update: 2021-02-17
In the European Union, Vimpat was first approved in September 2008 as an ancillary drug for the treatment of partial seizure epilepsy (accompanied or not accompanied by secondary comprehensive seizure epilepsy) in children, adolescents and adults aged 4 years and older.
-
Breast cancer targeted treatment! Novarce Kisqali performs in patients with incurable visceral metastasis HR-/HER2-advanced breast cancer:
Time of Update: 2021-02-17
The data showed that in patients with advanced breast cancer 2 negative (HR-/HER2-) pre-menopathic, peri-menopathic, post-menotinal hormone-positive, human skin growth factor(HR-/HER2-) advanced breast cancer, Kisqali combined endocrine therapy significantly extended progression-free survival (PFS) compared to endocrine alone treatment, regardless of whether the patient had visceral metastasis.
-
The innovative drug GLPG1792 has been awarded fast track status by the FDA
Time of Update: 2021-02-17
Recently, the company announced that the U.S. Food and Drug Administration (FDA) has granted GLPG 1972/S201086 fast-track status for the treatment of osteoarthritis (OA).
GLPG1972/S201086 was discovered by Galapagos and is being developed in collaboration with Schweija, with the potential to become a pioneering disease-modified osteoarthritis drug (DMOAD).
-
New drug for leukemia! Astellas second-generation FLT3 inhibitor Xospata has been approved by the FDA to treat relapse/difficulty:
Time of Update: 2021-02-17
FDA approval of Xospata is based on an interim analysis of the following endpoints in ADMIRAL clinical studies: Full Remission Rate (CR)/Complete Remission (CRh), CR/CRh Remission Duration (DOR), conversion rate dependent on blood transfusion to non-dependent blood transfusion.
-
Researchers have developed a third-generation new FLT3 kinase inhibition for the selective mutation of FLT3-ITD for acute myeloid leukemia.
Time of Update: 2021-02-17
In this work, the researchers developed a new FLT3-ITD mutation-selective type II kinase inhibitor CHMFL-FLT3-335, starting with the structure of the nonse specific FLT3 inhibitor AZD2932 and sorafinib (type II multi-target kinase inhibitor).
-
Non-limiting cancer-type heavy-weight targeted drugs were declared clinically accepted in China
Time of Update: 2021-02-17
, industry news that the company's heavyweight "unlimited cancer" target drug, Vitrakvi, which was bought by Lilly for $8 billion a few days ago, has declared clinical trials (INDs) in China and has been accepted.
![9-[1,1'-biphenyl]-4-yl-3,3'-Bi-9H-carbazole](https://file.echemi.com/fileManage/upload/category/ac71ac0d-8ef6-11ec-89e5-fa163ed06441.png)
